- Home
- VIGL vs EHTH Comparison
VIGL vs EHTH Comparison
Compare VIGL & EHTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- EHTH
- Stock Information
- Founded
- VIGL 2020
- EHTH 1997
- Country
- VIGL United States
- EHTH United States
- Employees
- VIGL N/A
- EHTH N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- EHTH Specialty Insurers
- Sector
- VIGL Health Care
- EHTH Finance
- Exchange
- VIGL Nasdaq
- EHTH Nasdaq
- Market Cap
- VIGL 141.5M
- EHTH 153.5M
- IPO Year
- VIGL 2022
- EHTH 2006
- Fundamental
- Price
- VIGL $3.00
- EHTH $4.95
- Analyst Decision
- VIGL Buy
- EHTH Buy
- Analyst Count
- VIGL 5
- EHTH 3
- Target Price
- VIGL $16.80
- EHTH $7.33
- AVG Volume (30 Days)
- VIGL 51.3K
- EHTH 230.0K
- Earning Date
- VIGL 11-07-2024
- EHTH 11-06-2024
- Dividend Yield
- VIGL N/A
- EHTH N/A
- EPS Growth
- VIGL N/A
- EHTH N/A
- EPS
- VIGL N/A
- EHTH N/A
- Revenue
- VIGL N/A
- EHTH $464,891,000.00
- Revenue This Year
- VIGL N/A
- EHTH $9.22
- Revenue Next Year
- VIGL N/A
- EHTH $6.32
- P/E Ratio
- VIGL N/A
- EHTH N/A
- Revenue Growth
- VIGL N/A
- EHTH 15.78
- 52 Week Low
- VIGL $2.47
- EHTH $3.58
- 52 Week High
- VIGL $6.06
- EHTH $9.45
- Technical
- Relative Strength Index (RSI)
- VIGL 32.87
- EHTH 50.96
- Support Level
- VIGL $2.89
- EHTH $5.14
- Resistance Level
- VIGL $3.26
- EHTH $5.42
- Average True Range (ATR)
- VIGL 0.22
- EHTH 0.36
- MACD
- VIGL -0.08
- EHTH -0.05
- Stochastic Oscillator
- VIGL 9.40
- EHTH 54.86
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About EHTH eHealth Inc.
eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare and Employer and Individual. It derives maximum revenue from Medicare Segment. All of the company's revenue is from the United States. It also has a presence in China.